---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-270462"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:33:24.132155+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology enters $300M at-the-market equity facility with TD Cowen

## Summary
- New Sales Agreement allows Vir to sell up to $300M of common stock through TD Cowen as agent.
- Commission of up to 3.0% on gross proceeds; Cowen may use customary at-the-market methods.
- Prior 2020 sales agreement with TD Cowen terminated; no shares were sold under the prior facility.
- Shares sold under existing S-3 shelf registration statement filed November 3, 2023.
- Company not obligated to sell any shares; facility provides optional capital-raising flexibility.

## SEC filing metadata
- accession: 0001193125-23-270462
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312523270462/0001193125-23-270462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312523270462/d567220d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-270462
- JSON: https://secwatch.observer/filing/0001193125-23-270462.json
- Plain text: https://secwatch.observer/filing/0001193125-23-270462.txt

## Key facts
- Material Agreements
  Vir Biotechnology, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $300.0 million (effective 2023-11-03).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Value: up to $300.0 million
  - Effective: 2023-11-03
  source text: On November 3, 2023, Vir Biotechnology, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC, as sales agent (“TD Cowen”), pursuant to which the Company may from time to time offer and sell shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $300.0 million, through or to TD Cowen, acting as sales agent or principal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523270462/0001193125-23-270462-index.htm
- Material Agreements
  Vir Biotechnology, Inc. terminated Prior Sales Agreement with TD Cowen (effective 2023-11-03).
  - Action: termination
  - Agreement: atm program
  - Counterparty: TD Cowen
  - Effective: 2023-11-03
  source text: On November 3, 2023, and in connection with entering into the Sales Agreement, the Company and TD Cowen agreed to terminate, effective as of immediately prior to the entry by the parties into the Sales Agreement, the sales agreement that the Company previously entered into with TD Cowen on November 10, 2020 (the “Prior Sales Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523270462/0001193125-23-270462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.